Innovent Biologics mazdutide can pave way for transformative T2D treatment: GlobalData GlobalData May 24, 2024 Mazdutide will be the second drug from Innovent Biologics in Chinese metabolic disorders market
New data for Roche’s Ocrevus show benefit in disability progression and cognitive decline in… EP News Bureau Apr 5, 2022 The treatment with Ocrevus resulted in a majority of patients experiencing no disease progression in a one-year analysis of…
Valneva says Chikungunya vaccine phase-III trial has met primary endpoint Reuters Dec 23, 2021 In August, after Valneva gave a positive update on the phase-III trial